BI/OND’s customizable Organ-on-Chips (OOCs) are built to outperform the limitation of standard in vitro assays.
BI/OND designs and develops microfluidic devices for in-vitro studies on complex 3D tissue cultures such as microtissues, organoids, patient-derived samples and tissue-tissue interfaces.
Comprising a six-well plate holder and disposable microfluidic chips, the devices are able to maintain tissue integrity while providing mechanical stimulation.
Used for 3D tissue-on-chip and organ-on-chip applications, the platform is compact and easy-to-use.
Microfluidic chips for in-vitro studies
BI/OND’s microfluidic chip comprises micro-channels located under an open well, which are connected through a porous membrane. This structure offers co-culture support to replicate a tissue-tissue interface.
The open well can accommodate a wide variety of samples, providing biologists with direct access to the cell culture. The microfluidic technology refreshes the medium around the tissue via the perfusion channel and provides nutrients. The chip is flexible and optically transparent for imaging.
Well plate for 3D cell cultures in clinical trials
BI/OND’s plate-like holder allows fluid flow, mechanical stimulation and imaging to support cells and 3D tissue cultures. It is compact, reusable and compatible with perfusion systems.
The holder supports up to six cultures in parallel, with the option to perfuse compartments with different flow rates.
The disposable chips can be removed from the holder for cell collection, as well as confocal and short distance microscopy.
3D tissue-on-chip applications for clinical research
BI/OND’s microfluidic platform is suitable for complex 3D tissue-on-chip applications, which can be used for diseases such as Parkinson’s disease and breast cancer research.
For complex 3D tissue models, the available options are:
- Disposable chips with three microfluidic channels
- Reusable six-well plate holder with a single or double flow (top and bottom of the tissue)
Organ-on-chip applications for personalised medicine
BI/OND’s microfluidic devices are used for organ-on-chip applications such as developing a heart model for studying cardiovascular functions and diseases.
Available organ-on-chip options include:
- Disposable chips with a single channel for better control of the flow conditions
- Reusable six-well plate holder with a single flow through the microchannel compartment
- Customisable membrane thickness and porosity for an optimal tissue-tissue interface
Customisable hardware solutions for research and development
BI/OND’s chips can be customised to meet client requirements, including options such as:
- The microfluidic channel can vary in height from 40µm to 120µm and include multiple channels
- The standard square-shaped open well can be altered to be rectangular or circular
- The membrane porosity can be adapted both in pore size (from 3µm to 20µm) and density (from 2% to 65% porosity)
The company invests in research and development (R&D) activities to create innovative hardware solutions.
BI/OND is an innovative Dutch biotech start-up company with broad expertise in microelectronics.
Based in Delft, the company supports contract research organisations (CRO) and biotech and pharmaceutical companies to conduct fundamental research into health by providing versatile, dynamic hardware for 2D and 3D tissue models.
BI/OND’s technologies enable biologists to achieve more realistic modelling.
The company offers an in-vitro alternative to animal testing. Organ-on-a-chip devices are among the technologies that could revolutionise the way drugs are being developed. Contact BI/OND using the enquiry form if you are developing an accurate human-representative system for disease models, seeking an alternative to animal models for your research or developing vitro models based on stem cells for personalised treatments.
BI/OND has won the Philips Innovator Award, receiving praise from the jury for being the best student start-up in the Netherlands.
BI/OND has teamed up with the Eindhoven University of Technology and Luxembourg University to develop a Midbrain-on-a-Chip model to treat Parkinson’s disease, which is the second most prevalent neurodegenerative disorder in the ageing population.